Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients
Systemic inflammation, endothelial dysfunction and coagulopathy are of high clinical relevance in the management of people living with HIV (PLWH), and even more in patients coinfected with hepatitis C virus (HCV). It has been suggested a significant impact of HCV coinfection on these conditions. How...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/8/2/323 |
| _version_ | 1797564773560221696 |
|---|---|
| author | Beatriz Álvarez Clara Restrepo Marcial García María A. Navarrete-Muñoz María A. Jiménez-Sousa Laura Prieto Alfonso Cabello Sara Nistal Salvador Resino Miguel Górgolas Norma Rallón José M. Benito |
| author_facet | Beatriz Álvarez Clara Restrepo Marcial García María A. Navarrete-Muñoz María A. Jiménez-Sousa Laura Prieto Alfonso Cabello Sara Nistal Salvador Resino Miguel Górgolas Norma Rallón José M. Benito |
| author_sort | Beatriz Álvarez |
| collection | DOAJ |
| description | Systemic inflammation, endothelial dysfunction and coagulopathy are of high clinical relevance in the management of people living with HIV (PLWH), and even more in patients coinfected with hepatitis C virus (HCV). It has been suggested a significant impact of HCV coinfection on these conditions. However, HCV can be eradicated in most patients with the new direct-acting antivirals (DAAs) therapy. We have analyzed the effect of HCV on systemic inflammation, endothelial activation and coagulopathy in PLWH and its evolution after HCV eradication with DAAs. Twenty-five HIV/HCV coinfected (HIV/HCV group), 25 HIV monoinfected (HIV group) and 20 healthy controls (HC) were included in the study. All patients were on ART and HIV suppressed. Levels of fourteen markers of systemic inflammation, endothelial activation and coagulopathy (IL-1ß, IL-6, IL-12p70, IL-8, TNFα, D-dimer, Eotaxin, IL-18, IP-10, monocyte chemotactic protein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1), TNFα receptor 1 (TNFR1), vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1)) were measured on plasma at baseline and after DAAs-mediated HCV eradication. Non-parametric tests were used to establish inter/intra-group differences. At baseline, the HIV/HCV group showed increased levels of IL-18 (<i>p</i> = 0.028), IP-10 (<i>p</i> < 0.0001), VCAM-1 (<i>p</i> < 0.0001) and ICAM-1 (<i>p</i> = 0.045), compared to the HC and HIV groups, with the highest levels for IL18 and IP10 observed in HIV/HCV patients with increased liver stiffness (≥7.1 KPa). Eradication of HCV with DAAs-based therapy restored some but not all the evaluated parameters. VCAM-1 remained significantly increased compared to HC (<i>p</i> = 0.001), regardless of the level of basal liver stiffness in the HIV/HCV group, and IP-10 remained significantly increased only in the HIV/HCV group, with increased level of basal liver stiffness compared to the HC and to the HIV groups (<i>p</i> = 0.006 and <i>p</i> = 0.049, respectively). These data indicate that DAAs therapy in HIV/HCV co-infected patients and HCV eradication does not always lead to the normalization of systemic inflammation and endothelial dysfunction conditions, especially in cases with increased liver stiffness. |
| first_indexed | 2024-03-10T19:02:39Z |
| format | Article |
| id | doaj.art-e049e8feaa90454897168bab7a108ce1 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T19:02:39Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-e049e8feaa90454897168bab7a108ce12023-11-20T04:20:48ZengMDPI AGVaccines2076-393X2020-06-018232310.3390/vaccines8020323Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected PatientsBeatriz Álvarez0Clara Restrepo1Marcial García2María A. Navarrete-Muñoz3María A. Jiménez-Sousa4Laura Prieto5Alfonso Cabello6Sara Nistal7Salvador Resino8Miguel Górgolas9Norma Rallón10José M. Benito11Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, SpainHIV and Viral Hepatitis Research Laboratory, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, SpainHIV and Viral Hepatitis Research Laboratory, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, SpainHIV and Viral Hepatitis Research Laboratory, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, SpainUnidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, 28040 Madrid, SpainHospital Universitario Fundación Jiménez Díaz, 28040 Madrid, SpainHospital Universitario Fundación Jiménez Díaz, 28040 Madrid, SpainHospital Universitario Rey Juan Carlos, 28933 Móstoles, SpainUnidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, 28040 Madrid, SpainHospital Universitario Fundación Jiménez Díaz, 28040 Madrid, SpainHIV and Viral Hepatitis Research Laboratory, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, SpainHIV and Viral Hepatitis Research Laboratory, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, SpainSystemic inflammation, endothelial dysfunction and coagulopathy are of high clinical relevance in the management of people living with HIV (PLWH), and even more in patients coinfected with hepatitis C virus (HCV). It has been suggested a significant impact of HCV coinfection on these conditions. However, HCV can be eradicated in most patients with the new direct-acting antivirals (DAAs) therapy. We have analyzed the effect of HCV on systemic inflammation, endothelial activation and coagulopathy in PLWH and its evolution after HCV eradication with DAAs. Twenty-five HIV/HCV coinfected (HIV/HCV group), 25 HIV monoinfected (HIV group) and 20 healthy controls (HC) were included in the study. All patients were on ART and HIV suppressed. Levels of fourteen markers of systemic inflammation, endothelial activation and coagulopathy (IL-1ß, IL-6, IL-12p70, IL-8, TNFα, D-dimer, Eotaxin, IL-18, IP-10, monocyte chemotactic protein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1), TNFα receptor 1 (TNFR1), vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1)) were measured on plasma at baseline and after DAAs-mediated HCV eradication. Non-parametric tests were used to establish inter/intra-group differences. At baseline, the HIV/HCV group showed increased levels of IL-18 (<i>p</i> = 0.028), IP-10 (<i>p</i> < 0.0001), VCAM-1 (<i>p</i> < 0.0001) and ICAM-1 (<i>p</i> = 0.045), compared to the HC and HIV groups, with the highest levels for IL18 and IP10 observed in HIV/HCV patients with increased liver stiffness (≥7.1 KPa). Eradication of HCV with DAAs-based therapy restored some but not all the evaluated parameters. VCAM-1 remained significantly increased compared to HC (<i>p</i> = 0.001), regardless of the level of basal liver stiffness in the HIV/HCV group, and IP-10 remained significantly increased only in the HIV/HCV group, with increased level of basal liver stiffness compared to the HC and to the HIV groups (<i>p</i> = 0.006 and <i>p</i> = 0.049, respectively). These data indicate that DAAs therapy in HIV/HCV co-infected patients and HCV eradication does not always lead to the normalization of systemic inflammation and endothelial dysfunction conditions, especially in cases with increased liver stiffness.https://www.mdpi.com/2076-393X/8/2/323systemic inflammationendothelial activationHIV/HCV coinfectionliver stiffnessHCV eradicationDAAs |
| spellingShingle | Beatriz Álvarez Clara Restrepo Marcial García María A. Navarrete-Muñoz María A. Jiménez-Sousa Laura Prieto Alfonso Cabello Sara Nistal Salvador Resino Miguel Górgolas Norma Rallón José M. Benito Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients Vaccines systemic inflammation endothelial activation HIV/HCV coinfection liver stiffness HCV eradication DAAs |
| title | Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients |
| title_full | Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients |
| title_fullStr | Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients |
| title_full_unstemmed | Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients |
| title_short | Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients |
| title_sort | liver stiffness hinders normalization of systemic inflammation and endothelial activation after hepatitis c virus hcv eradication in hiv hcv coinfected patients |
| topic | systemic inflammation endothelial activation HIV/HCV coinfection liver stiffness HCV eradication DAAs |
| url | https://www.mdpi.com/2076-393X/8/2/323 |
| work_keys_str_mv | AT beatrizalvarez liverstiffnesshindersnormalizationofsystemicinflammationandendothelialactivationafterhepatitiscvirushcveradicationinhivhcvcoinfectedpatients AT clararestrepo liverstiffnesshindersnormalizationofsystemicinflammationandendothelialactivationafterhepatitiscvirushcveradicationinhivhcvcoinfectedpatients AT marcialgarcia liverstiffnesshindersnormalizationofsystemicinflammationandendothelialactivationafterhepatitiscvirushcveradicationinhivhcvcoinfectedpatients AT mariaanavarretemunoz liverstiffnesshindersnormalizationofsystemicinflammationandendothelialactivationafterhepatitiscvirushcveradicationinhivhcvcoinfectedpatients AT mariaajimenezsousa liverstiffnesshindersnormalizationofsystemicinflammationandendothelialactivationafterhepatitiscvirushcveradicationinhivhcvcoinfectedpatients AT lauraprieto liverstiffnesshindersnormalizationofsystemicinflammationandendothelialactivationafterhepatitiscvirushcveradicationinhivhcvcoinfectedpatients AT alfonsocabello liverstiffnesshindersnormalizationofsystemicinflammationandendothelialactivationafterhepatitiscvirushcveradicationinhivhcvcoinfectedpatients AT saranistal liverstiffnesshindersnormalizationofsystemicinflammationandendothelialactivationafterhepatitiscvirushcveradicationinhivhcvcoinfectedpatients AT salvadorresino liverstiffnesshindersnormalizationofsystemicinflammationandendothelialactivationafterhepatitiscvirushcveradicationinhivhcvcoinfectedpatients AT miguelgorgolas liverstiffnesshindersnormalizationofsystemicinflammationandendothelialactivationafterhepatitiscvirushcveradicationinhivhcvcoinfectedpatients AT normarallon liverstiffnesshindersnormalizationofsystemicinflammationandendothelialactivationafterhepatitiscvirushcveradicationinhivhcvcoinfectedpatients AT josembenito liverstiffnesshindersnormalizationofsystemicinflammationandendothelialactivationafterhepatitiscvirushcveradicationinhivhcvcoinfectedpatients |